Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 153

Results For "NITI"

3245 News Found

President Murmu to inaugurate homeopathic symposium on World Homoeopathy Day 2024
News | April 10, 2024

President Murmu to inaugurate homeopathic symposium on World Homoeopathy Day 2024

Empowering Research, Enhancing Proficiency is the theme of this year’s Homoeopathic Symposium


Wacker and Pantherna intensify collaboration in the development and production of mRNA biopharmaceuticals
Biotech | April 07, 2024

Wacker and Pantherna intensify collaboration in the development and production of mRNA biopharmaceuticals

Wacker Biotech is a CDMO for the GMP-compliant production of active ingredients for the pharmaceutical industry


Imfinzi significantly improved overall survival and progression-free survival in ADRIATIC Phase III trial
Clinical Trials | April 06, 2024

Imfinzi significantly improved overall survival and progression-free survival in ADRIATIC Phase III trial

First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial


Aster DM Healthcare concludes separation of India and GCC businesses
Healthcare | April 05, 2024

Aster DM Healthcare concludes separation of India and GCC businesses

The company plans to add 1700 beds by FY27 through the organic route


Dabur India expects mid-single digit revenue growth in Q4
News | April 05, 2024

Dabur India expects mid-single digit revenue growth in Q4

International Business is expected to register double-digit growth in constant currency terms


Max CMD Abhay Soi is new president of NATHEALTH
People | April 04, 2024

Max CMD Abhay Soi is new president of NATHEALTH

New leadership team announced at NATHEALTH Annual General Meeting 2024


EC expands Reblozyl’s approval for treatment of myelodysplastic syndromes
Drug Approval | April 03, 2024

EC expands Reblozyl’s approval for treatment of myelodysplastic syndromes

This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia


Zydus receives approval for the name 'Usnoflast' as recommended name for ZYIL1 from WHO  International Non-proprietary Names
News | April 02, 2024

Zydus receives approval for the name 'Usnoflast' as recommended name for ZYIL1 from WHO International Non-proprietary Names

Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus